Heterogeneous treatment effects of dexamethasone 12 mg versus 6 mg in patients with COVID‐19 and severe hypoxaemia—Post hoc exploratory analyses of the COVID STEROID 2 trial

BACKGROUND: Corticosteroids improve outcomes in patients with severe COVID‐19. In the COVID STEROID 2 randomised clinical trial, we found high probabilities of benefit with dexamethasone 12 versus 6 mg daily. While no statistically significant heterogeneity in treatment effects (HTE) was found in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Granholm, Anders, Munch, Marie Warrer, Andersen‐Ranberg, Nina, Myatra, Sheila Nainan, Vijayaraghavan, Bharath Kumar Tirupakuzhi, Venkatesh, Balasubramanian, Jha, Vivekanand, Wahlin, Rebecka Rubenson, Jakob, Stephan M., Cioccari, Luca, Møller, Morten Hylander, Perner, Anders
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Intensive Care and Physiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9874464/
https://www.ncbi.nlm.nih.gov/pubmed/36314057
http://dx.doi.org/10.1111/aas.14167

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9874464/
https://www.ncbi.nlm.nih.gov/pubmed/36314057
http://dx.doi.org/10.1111/aas.14167

Ejemplares similares